Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients undergoing neoadjuvant chemotherapy: A systematic review and meta-analysis

Table 1 Baseline characteristics of the included literature

Ref.	Study period	Country	Study design	Time of test	Population	Neoadjuvant chemotherapy	Patients (n)	Gender		Age	NLR threshold
								Male	Female
Gong et al[13]	2007-2015	China	Retrospective	Before and after NAC	II-III	DOF, DF, FOLFOX	91	69	22	55	1.05
Jin et al[17]	2004-2009	China	Retrospective	Before and after NAC	III-IV	FOLFOX	46	36	10	60	2.50
el Aziz[19]	2010-2014	Egypt	Retrospective	Before NAC	III-IV	FOLFOX	70	47	23	53	3.00
Liu et al[15]	2016-2019	China	Retrospective	Before and after NAC	II-III	SOX, XELOX	111	83	28	58	1.75
Kasahara et al[20]	2011-2016	Japan	Retrospective	Before and after NAC	II	S-1	47	30	17	66	2.41
Chen et al[16]	2008-2015	China	Retrospective	Before NAC	II-III	SOX, XELOX	91	70	21	57	2.17
Zurlo et al[23]	2012-2017	Rome	Retrospective	Before and after NAC	III B-III C	XELOX, DOF	65	41	24	63	2.50
Pikuła et al[22]	2012-2020	Poland	Retrospective	Before and after NAC	II-III	EOX, FLOT-4	106	65	41	61	1.94
Li et al[21]	2014-2018	China	Prospective	Before and after NAC	II-IV A	DOF	225	172	53	60	2.57

NAC: Neoadjuvant chemotherapy; NLR: Neutrophil to lymphocyte ratio; DOF: Doxorubicin + oxaliplatin + fluorouracil; DF: Doxorubicin + fluorouracil; FOLFOX: Fluorouracil + oxaliplatin + calcium folinate; SOX: S-1 + oxaliplatin; XELOX: Oxaliplatin + capecitabine; S-1: Tegafur; EOX: Epirubicin + oxaliplatin + capecitabine; FLOT-4: Fluorouracil + oseltamivir + folinate + tegafur.